Deerfield Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Deerfield Management’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-83,846	Closed	-$5.57M	–	151
2021 Q3	$5.57M	Hold	83,846	–	–	0.11%	111
2021 Q2	$6.54M	Hold	83,846	–	–	0.12%	123
2021 Q1	$7.93M	Hold	83,846	–	–	0.17%	108
2020 Q4	$10.2M	Buy	+83,846	New	+$9.19M	0.2%	104
2020 Q3	–	Sell	-188,490	Closed	-$12.2M	–	121
2020 Q2	$12.2M	Sell	188,490 -224,831	-54%	-$13M	0.35%	71
2020 Q1	$18.5M	Buy	413,321 +47,321	+13%	+$2.51M	0.59%	54
2019 Q4	$22.8M	Sell	366,000 -21,545	-6%	-$1.03M	0.73%	43
2019 Q3	$14.6M	Buy	387,545 +100,000	+35%	+$4.35M	0.59%	53
2019 Q2	$11.7M	Buy	+287,545	New	+$10.3M	0.42%	68

Other funds holding TPTX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Deerfield Management's TPTX Position: Q4 2021 in Review

Deerfield Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q4 2021, closing a stake of 83,846 shares — an estimated $5.57M sold.

Deerfield Management first reported a position in TPTX in Q2 2019 and held it in 9 quarters. The position peaked at $22.8M in Q4 2019. 172 funds tracked by Wall St. Rank hold TPTX as of Q4 2021.

Deerfield Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Deerfield Management sold 83,846 Turning Point Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $5.57M.
Deerfield Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 9 quarters.
Deerfield Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $22.8M in Q4 2019.
172 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Deerfield Management's 13F filing for Q4 2021, filed 14 Feb 2022.